Login to Your Account



Pharma: Clinic Roundup


Wednesday, June 26, 2013
Boehringer Ingelheim Pharmaceuticals GmbH., of Ingelheim, Germany, and Eli Lilly and Co., of Indianapolis, disclosed a pooled analysis of Phase III data for the dipeptidyl peptidase-4 inhibitor linagliptin.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription